New Pipeline Therapies Poised to Transform CIDP Market by 2036

The treatment landscape for this rare autoimmune disorder is shifting away from traditional intravenous immunoglobulin and corticosteroids toward targeted, mechanism-based interventions. Pharmaceutical developers are currently prioritizing candidates such as Sanofi’s Riliprubart, Immunovant’s Batoclimab, and argenx’s Empasiprubart. These assets aim to address current clinical shortcomings, specifically the slow onset of action and safety profiles associated with older medication classes.

Market analysis covering the United States, EU4, the United Kingdom, and Japan indicates that the United States remains the largest segment for treatment expenditure. Industry experts note that while standard therapies continue to hold the bulk of the market share, the introduction of subcutaneous formulations and FcRn inhibitors is actively improving patient compliance and home-based care options. With clinical research activities intensifying, including Phase III trials for several high-profile candidates, the coming decade is expected to see a fundamental change in how clinicians manage relapsing and progressive nerve injury.